← Leaderboards
Justin Richard Bailey
Johns Hopkins University
$16,021,335
Attributed
$16,847,322
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,847,322 · 10
By mechanism
R01$10,297,800 · 3
U19$3,511,688 · 4
R24$1,651,974 · 1
K08$935,547 · 1
R21$450,313 · 1
Top collaborators
- Mansun Law3 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- David L Thomas$44,227,388
- Andrea L Cox$41,369,991
- Shruti H Mehta$41,677,787
- Chloe L Thio$13,807,555
- Stuart C Ray$7,743,036
Others in their field
Top investigators on “Neutralizing Antibody”
- Barton F Haynes · Duke University$361,488,167
- Dennis R. Burton · Scripps Research Institute$328,455,703
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$262,392,049
- Lawrence Corey · Fred Hutchinson Cancer Center$257,355,255
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$139,509,763
Research focus
Neutralizing AntibodyAntibodiesMonoclonal AntibodiesEpitopesInfectionAntibody ResponseBindingB-LymphocytesViralVirusIn VitroVaccine DevelopmentVaccinesHepatitis C VaccineMolecularChronicPlasmaResponseHepatitis C VirusVirus DiseasesAffinityB Cell RepertoireEnv Gene ProductsHepatitis C
Grant awards (32)
Immune response dynamics and hepatitis B cure in persons with and without HIV infection$822,835
U19 · FY2025 · AI · contact PI
Neutralizing antibody responses during natural control of acute hepatitis B with and without HIV-1 coinfection$812,575
R01 · FY2025 · AI · contact PI
Molecular and structural characterization of broadly neutralizing anti-HCV antibodies$780,775
R01 · FY2025 · AI · contact PI
Mechanisms of antibody-mediated control of repeated hepatitis C virus infection in humans$397,972
U19 · FY2025 · AI · contact PI
The role of neutralizing antibodies in natural and treatment-induced control of hepatitis B with and without HIV-1 co-infection$368,297
R01 · FY2025 · AI · contact PI
Neutralizing antibody responses during natural control of acute hepatitis B with and without HIV-1 coinfection$812,575
R01 · FY2024 · AI · contact PI
Molecular and structural characterization of broadly neutralizing anti-HCV antibodies$804,923
R01 · FY2024 · AI · contact PI
Mechanisms of antibody-mediated control of repeated hepatitis C virus infection in humans$538,301
U19 · FY2024 · AI · contact PI
The role of neutralizing antibodies in natural and treatment-induced control of hepatitis B with and without HIV-1 co-infection$391,926
R01 · FY2024 · AI · contact PI
Molecular and structural characterization of broadly neutralizing anti-HCV antibodies$820,861
R01 · FY2023 · AI · contact PI
Neutralizing antibody responses during natural control of acute hepatitis B with and without HIV-1 coinfection$794,719
R01 · FY2023 · AI · contact PI
Mechanisms of antibody-mediated control of repeated hepatitis C virus infection in humans$555,279
U19 · FY2023 · AI · contact PI
Development of standardized immunoassays and virus panels for HCV vaccine research$542,012
R24 · FY2023 · AI · contact PI
The role of neutralizing antibodies in natural and treatment-induced control of hepatitis B with and without HIV-1 co-infection$341,682
R01 · FY2023 · AI · contact PI
Neutralizing antibody responses during natural control of acute hepatitis B with and without HIV-1 coinfection$766,615
R01 · FY2022 · AI · contact PI
Mechanisms of antibody-mediated control of repeated hepatitis C virus infection in humans$544,334
U19 · FY2022 · AI · contact PI
Development of standardized immunoassays and virus panels for HCV vaccine research$542,012
R24 · FY2022 · AI · contact PI
Molecular and structural characterization of broadly neutralizing anti-HCV antibodies$709,188
R01 · FY2021 · AI · contact PI
Development of standardized immunoassays and virus panels for HCV vaccine research$567,950
R24 · FY2021 · AI · contact PI
Mechanisms of antibody-mediated control of repeated hepatitis C virus infection in humans$516,331
U19 · FY2021 · AI · contact PI
Development of a single-cell antibody cloning protocol for isolation of hepatitis C virus-specific broadly neutralizing antibodies$204,688
R21 · FY2021 · AI · contact PI
Molecular and structural characterization of broadly neutralizing anti-HCV antibodies$709,381
R01 · FY2020 · AI · contact PI
Development of a single-cell antibody cloning protocol for isolation of hepatitis C virus-specific broadly neutralizing antibodies$245,625
R21 · FY2020 · AI · contact PI
Molecular and structural characterization of broadly neutralizing anti-HCV antibodies$719,568
R01 · FY2019 · AI · contact PI
Molecular and structural characterization of broadly neutralizing anti-HCV antibodies$719,898
R01 · FY2018 · AI · contact PI
Molecular and structural characterization of broadly neutralizing anti-HCV antibodies$744,817
R01 · FY2017 · AI · contact PI
Mechanisms of Neutralizing Antibody Resistance in Chronic HCV and HIV Infection$195,063
K08 · FY2017 · AI · contact PI
Mechanisms driving breadth of HCV neutralization during repeated control of acute infection in humans$136,636
U19 · FY2017 · AI · contact PI
Mechanisms of Neutralizing Antibody Resistance in Chronic HCV and HIV Infection$185,121
K08 · FY2016 · AI · contact PI
Mechanisms of Neutralizing Antibody Resistance in Chronic HCV and HIV Infection$185,121
K08 · FY2015 · AI · contact PI
Mechanisms of Neutralizing Antibody Resistance in Chronic HCV and HIV Infection$185,121
K08 · FY2014 · AI · contact PI
Mechanisms of Neutralizing Antibody Resistance in Chronic HCV and HIV Infection$185,121
K08 · FY2013 · AI · contact PI